Le Lézard
Classified in: Health
Subject: AWD

LIVFRESH Earns Coveted Spot as Best Toothpaste in GQs Magazine's 2019 Grooming Awards - November Issue


SAN FRANCISCO, Nov. 13, 2019 /PRNewswire-PRWeb/ -- Today, Livionex announces its newly launched LIVFRESH dental gel line has earned a spot as one of the '41 Best Grooming Products for Men in 2019' in GQ Magazine's November Grooming Awards issue.

LIVFRESH was referred to as "The only useful thing to come out of Silicon Valley: a lightweight, investor-backed, science-y gel that makes teeth feel squeaky clean," according the GQ Magazine article.

"We are thrilled to have LIVFRESH included as a 2019 GQ Grooming Awards' winner in this magazine that is highly recognized as the leader in men's grooming and fashion," said Livionex CEO Amit Goswamy.

"Research has shown that men have a higher incidence of periodontal disease than women. We couldn't be happier that GQ recognizes just how critical it is that their readers implement a preventative dental care routine. Our LIVFRESH line is dentist-recommended as well as clinically proven, in published studies, to clean teeth and remove plaque (the root cause of periodontal disease), 250% better than the leading brands," added Goswamy.

The LIVFRESH line includes LIVFRESH Peppermint, LIVFRESH Wintergreen and LIVFRESH Mild Peppermint. All three gels use 100% edible ingredients to eliminate bad breath, prevent tartar formation, and re-mineralize enamel.

What's different about LIVFRESH, than other toothpastes, is that it uses activated edathamil in a new technology that removes plaque from the teeth at the molecular level. Additionally, LIVFRESH doesn't use abrasives, antimicrobials, and parabens found in major toothpaste brands; as a result, it is safe for all ages including young children and pregnant women. The products are cruelty-free, gluten-free, and vegan.

The plaque-disrupting technology underlying LIVFRESH has been validated by numerous sources, including dental professionals, the U.S. Department of Defense, and the National Institutes of Health .

For more information, please visit GetLIVFRESH.com.

About LIVIONEX
Livionex was founded in 2009 by Stanford and Berkeley alums with the goal of enhancing the quality and longevity of human life. Headquartered in Los Gatos, CA, Livionex develops novel therapies for a variety of age-related diseases affecting billions of people worldwide. The Company's products are based on its proprietary technology that modulates metal ions that cause oxidative stress and disease. The Company is introducing a new category of treatment for various disorders and diseases associated with metallo lipid protein aggregates, inflammation, and/or bacterial biofilms across ophthalmology, dermatology and oral care. Livionex recently accepted $4 million in Series A funding at a $180-million valuation to further accelerate the market penetration of its dental gel line. LIVFRESH Dental Gel is currently available on-line at GetLIVFRESH.com and in dental offices across the country.

 

SOURCE LIVFRESH


These press releases may also interest you

at 03:30
Proprietary E3 ligase platform to enable protein stabilisation "at source", thereby restoring the body's sophisticated natural disease suppression processes Platform scales the assessment of E3 ligase targets while addressing the historic challenges...

at 03:00
Todd Britten, DMD, a board-certified periodontist and dental implant specialist in...

at 03:00
SK chemicals (CEO Ahn Jae-hyun), Dongsung Chemical (Co-CEOs Baek Jin-woo and Lee Man-woo), and BYN Black Yak (Chairman Kang Tae-sun, hereinafter Black Yak) announced on the 18th that they've developed sustainable footwear materials using the...

at 02:55
First quarter  Sales of SEK 841 (854) million, a flat growth in local currencies and a decrease of 2% in SEK.Sales per region, in local currencies was +19% in APAC, -2% in EMEA and -14% in Americas.Sales per business area, in local currencies was...

at 02:05
PureTech Health plc ("PureTech" or the "Company") plans to publish its Annual Report and Accounts and financial results for the year ended December 31, 2023, on Thursday, April 25, 2024. A presentation and conference call to discuss the results...

at 02:05
Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and year-end report for January to March 2024. Highlights for the first quarter of 2024      Strong commercial...



News published on and distributed by: